Cell Surface Markers Market To Reach USD 965.0 Million By 2026 | Reports And Data
18 juil. 2019 10h33 HE
|
Reports and Data
New York, July 18, 2019 (GLOBE NEWSWIRE) -- The technological advancements in the health care sector, increased in rate of occurrence of cancer, and rise in investment in research and developments...
Lans Holdings Enters into Binding LOI to Acquire Global Stem Cells Group
28 mai 2019 08h00 HE
|
Lans Holdings Inc.
MIAMI, FL, May 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Lans Holdings Inc. (OTCPink: LAHO) is pleased to announce that it has entered into a binding letter of intent to acquire 100%...
International Stem Cell Corporation Announces Operating Results for the Quarter Ended March 31, 2019
17 mai 2019 08h30 HE
|
International Stem Cell Corporation
CARLSBAD, Calif., May 17, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage...
3D Cell Culture Market To Reach USD 1.99 Billion By 2026 | Reports And Data
25 avr. 2019 13h24 HE
|
Reports And Data
The government and non-government investments in cancer research & development, coupled with the large scale end uses of stem cell research are influencing the market growth. Market Size – USD...
International Stem Cell Corporation Announces 2018 Fourth Quarter and Year-End Results
15 avr. 2019 08h30 HE
|
International Stem Cell Corporation
CARLSBAD, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQX: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage...
Hemostemix Announces Appointment of Experienced Chief Medical Officer & President
01 avr. 2019 08h30 HE
|
Hemostemix Inc.
CALGARY, Alberta, April 01, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that Dr. Alan J. Jacobs, M.S.EE, M.D,...
Hemostemix Announces UC Davis Health Added as a Trial Site for Phase II Clinical Trial
25 févr. 2019 08h30 HE
|
Hemostemix Inc.
CALGARY, Alberta, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from UC...
Hemostemix Provides Highlights of 2018 Accomplishments
17 janv. 2019 08h30 HE
|
Hemostemix Inc.
CALGARY, Alberta, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following corporate update on...
Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical Trial
03 janv. 2019 08h00 HE
|
Hemostemix Inc.
CALGARY, Alberta, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from two...
Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01 Neural Cellular Precursors
09 nov. 2018 08h30 HE
|
Hemostemix Inc.
CALGARY, Alberta, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to provide the following update on its research and...